Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2023-12-19 Regulatory Filings
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-12-19 English
Regulatory Filings 2023
Regulatory Filings
2023-12-18 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2023-11-29 English
Regulatory Filings 2023
Regulatory Filings
2023-11-27 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2023, by Collegium Pharmaceutical, Inc. The content describes the execution of an accelerated share repurchase agreement (ASR) to repurchase $25 million of the company's common stock as part of a previously authorized $100 million share repurchase program. The document details the terms of the ASR agreement, including the initial delivery of shares and the expected final settlement date. This is a clear update on the company's share repurchase activity, which falls under capital structure changes and financing activities. The document is not a full financial report, earnings release, or management discussion, but rather a specific announcement about financing activity related to share repurchases. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 5679 characters, which is sufficient to contain substantive information about the financing event, not merely an announcement of a report publication or a regulatory filing. Confidence in this classification is high due to the explicit description of the share repurchase agreement and its financial terms.
2023-11-09 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.